Recently, WDR5, a subunit of the SET1/MLL (mixed lineage leukemia) complex, has been suggested as a major driver of AR-dependent prostate cancer [43] and has been shown to interact with H3T11P to guide MLL1 to the AR target gene site and promote H3K4me3. Here, KMT2A is linked to prostate carcinoma.